{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T14:24:26Z","timestamp":1720535066392},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2181,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1093\/annonc\/mdt466","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T14:52:28Z","timestamp":1385045548000},"page":"x33-x34","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S10","title":["Surgical intervention in relapsed ovarian cancer is beneficial: pro"],"prefix":"10.1016","volume":"24","author":[{"given":"P.","family":"Harter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hilpert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt466_bb0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","article-title":"Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer","volume":"121","author":"Harter","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt466_bb0015","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt466_bb0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/era.09.165","article-title":"Systemic therapy in recurrent ovarian cancer\u2014actual treatment options and new drugs","volume":"10","author":"Harter","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdt466_bb0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6\u201312 months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt466_bb0030","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt466_bb0035","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2217\/fon.12.112","article-title":"The changing landscape of therapeutic strategies for recurrent ovarian cancer","volume":"8","author":"Baumann","year":"2012","journal-title":"Future Oncol"},{"key":"10.1093\/annonc\/mdt466_bb0040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt466_bb0045","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt466_bb0050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt466_bb0055","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdt466_bb0060","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jso.21491","article-title":"Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1\u20131 cm after secondary cytoreduction","volume":"101","author":"Tian","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1093\/annonc\/mdt466_bb0065","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jso.21652","article-title":"Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients","volume":"102","author":"Sehouli","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1093\/annonc\/mdt466_bb0070","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","article-title":"Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis","volume":"16","author":"Harter","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdt466_bb0075","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdt466_bb0080","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdt466_bb0085","first-page":"CD007822","article-title":"Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer","volume":"6","author":"Galaal","year":"2010","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/suppl_10\/x33\/6674494\/mdt466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T09:54:17Z","timestamp":1597053257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419373880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":16,"alternative-id":["S0923753419373880"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt466","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}